Autolus Therapeutics Ltd (AUTL)

Currency in USD
2.520
-0.120(-4.55%)
Closed·
After Hours
2.600+0.080(+3.17%)
·

AUTL Earnings

Latest Release
May 08, 2025
EPS / Forecast
-0.26 / -0.26
Revenue / Forecast
2.10M / 1.42M
EPS Revisions
Last 90 days
Release Date
Period End
EPS
/Forecast
Revenue
/Forecast
EPS Surprise %
Revenue Surprise %
Reaction
06/2025--/-0.23--/12.91M----Free Sign Up
03/2025-0.26/-0.262.1M/1.42M0%+47.89%Free Sign Up
12/2024-0.09/-0.20629K/601K+56.31%-95.17%Free Sign Up
09/2024-0.31/-0.21187.5K/193.75K-47.62%-3.23%Free Sign Up
06/2024-0.22/-0.195--/93.75K-13.11%-100%Free Sign Up
03/2024-0.24/-0.0810.09M/33.4M-200%-69.79%Free Sign Up
12/2023-0.44/-0.43--/358.4K-2.33%-100%Free Sign Up
09/2023-0.26/-0.25403K/624.8K-4%-35.5%Free Sign Up
06/2023-0.26/-0.22--/136.5K-18.18%-100%Free Sign Up
03/2023-0.23/-0.27--/187.5K+14.81%-100%Free Sign Up

All numbers in USD

Autolus Therapeutics Ltd Earnings Call Summary for Q4/2024

  • Net loss increased to $220.7M in 2024, up from $208.4M in 2023; cash reserves rose to $588M due to BioNTech collaboration and equity financing
  • FDA approved Ocassol without REMS program; company plans to expand to 60 centers by year-end, targeting EU and UK regulatory submissions in 2025
  • Stock price dipped 0.26% to $1.94 post-earnings; market cap at $518.67M with strong liquidity but rapid cash burn noted by InvestingPro
  • No 2025 sales guidance provided; CEO and CFO express confidence in launch and commercialization plans for obiCELL
  • Analysts focused on outpatient administration potential and manufacturing consistency during Q&A, crucial for planned market expansion
Last Updated: 20/03/2025, 14:52
Read Full Transcript

FAQ

What Is Autolus Therapeutics's Earnings Per Share (TTM)?

The Autolus Therapeutics EPS (TTM) is -0.89.

When Is The Next Autolus Therapeutics Earnings Date?

Autolus Therapeutics will release its next earnings report on 11 Aug 2025.

What Is Autolus Therapeutics’s Revenue Forecasts For Upcoming Quarters?

Autolus Therapeutics’s revenue forecast is 12.91M.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.